- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
Accord BioPharma Launches Camcevi for Advanced Prostate Cancer
Camcevi is the first ready-to-inject sterile formulation of leuprolide mesylate for subcutaneous injection that comes in a pre-filled syringe with no mixing required.
Accord BioPharma, the U.S. specialty division of Intas Pharmaceuticals, has launched Camcevi (leuprolide) 42mg injection emulsion for the treatment of advanced prostate cancer in adults.
Accord BioPharma is offering eligible patients commercial copay assistance solutions, patient assistance programs, and a nurse-staffed clinical hotline that provides answers to questions from patients. The company also offers healthcare professionals access to AccordConnects, a mobile application designed to help healthcare practices manage in-practice inventory
The FDA approved Camcevi on May 25, 2021. It was approved based on data from an open-label, single-arm study of 137 adults that found that Camcevi offered consistent testosterone suppression to castrate levels. The most common adverse reactions were hot flush, hypertension, injection site reactions, upper respiratory tract infections, musculoskeletal pain, fatigue, and pain in extremity.
